Carsten Thiel has been making an impact on the pharmaceutical world for several years. Currently Thiel has nearly three decades of experience working in the this field and has changed the way that many members of the pharmaceutical industry conduct their business. His work has made an impact on people across the globe.
Carsten Thiel is a native of Berlin, Germany. At a young age he quickly built an interest in chemistry and the sciences. His desire for an Anglo-Saxon educational system lead him to a college outside of the country. Thiel attended the University of Bristol in the southwest of the UK. He soon earned his degree in biochemistry and went on to study at the renowned Max Planck Institute for Biophysical Chemistry. He would soon earn a PhD in Molecular Biology.
Carsten Thiel recently made major news when it was announced he was receiving a major promotion. EUSA Pharma that Carsten Thiel was becoming the president and will along side Darrel P. Cohen who will be Head of Clinical Development. Both Thiel and Cohen have extensive pharmaceutical experience that they bring to their new positions. Thiel’s resume includes a number of leadership positions. He has served as CEO of Abeona Therapeutics Inc. He also spent several years working as the Chief Commercial Officer at Alexion Pharmaceuticals Inc., a rare disease leader.
When speaking of his new position it was clear that Carsten Thiel is very excited about this new opportunity. Thiel is impressed by the progress that EUSA Pharma has made building a strong oncology and rare disease business. He is both honored and excited about working to lead the expansion of the company’s activities in Europe. Carsten Thiel is an innovator and a leader who is constantly working to take the pharmaceutical world to the next level.
Read More: www.crunchbase.com/person/carsten-thiel